a lipoprotein - HEALTHY
The American Journal of Managed Care: Elevated Lipoprotein(a) Increases Cardiovascular Risk Independently of SMuRFs How lipoprotein(a) (Lp[a]) affects cardiovascular (CV) risk, particularly in the context of major adverse CV events (MACE) among patients based on the baseline atherosclerotic CV disease (ASCVD) ... Elevated lipoprotein(a) levels can slowly block the arteries, increasing the likelihood of cardiovascular disease. Since no treatment is currently available for this condition, it is essential to ...
Context Explanation
MedPage Today: Lipoprotein(a) and Long-Term Heart Risks: Study Makes the Case for Screening Thirty-year outcomes among participants in the Women's Health Study showed a stepwise increase in major cardiovascular events associated with increasing lipoprotein(a) levels starting around 30-60 ... The Times Leader: To Your Health: Lipoprotein (a) increases risk of heart disease Today is Lipoprotein (a) Awareness Day, and it’s a great opportunity to discuss lipids and howlipoprotein (a) might differ from your general understanding of how cholesterol works in our bodies. Medical Xpress: Extremely elevated lipoprotein(a) levels tied to 30-year heart risk in women Brigham and Women's Hospital investigators link very high lipoprotein(a) with a higher 30-year risk of major cardiovascular events in initially healthy women. Elevated plasma lipoprotein(a) is a ...
Image Collection
Insight Material
Business Wire: Lipoprotein(a) Foundation: Did You Know That 63 Million Americans Have a High Risk of Inherited Cardiovascular Disease and May Not Know It? SAN CARLOS, Calif.--(BUSINESS WIRE)--Lipoprotein(a) Foundation: Lipoprotein(a), also known as Lp(a), is currently the strongest monogenetic risk factor for coronary heart disease and aortic stenosis. Lipoprotein(a) Foundation: Did You Know That 63 Million Americans Have a High Risk of Inherited Cardiovascular Disease and May Not Know It? Science Daily: Experimental ‘gene silencing’ therapy reduces lipoprotein(a), an important risk factor of heart disease, by up to 98% Findings from a phase 1 trial show that an experimental 'gene silencing' therapy reduced blood levels of lipoprotein(a), a key driver of heart disease risk, by up to 98%. Findings from a new Cleveland ...
Related Articles You Might Like:
vasculitic rash on legs pictures seborrheic dermatitis derm net daily recommended potassiumFinal Conclusion
Experimental ‘gene silencing’ therapy reduces lipoprotein(a), an important risk factor of heart disease, by up to 98%